Medical Oncology

, 34:64 | Cite as

Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy

  • Amrita Singh
  • Navneet Singh
  • Digambar Behera
  • Siddharth Sharma
Original Paper


Survival in lung cancer patients is genetically determined. Single nucleotide polymorphisms (SNPs) in DNA repair genes are observed to play a critical role in survival as DNA repair itself can behave as double-edged sword. We aim to explore the association of DNA repair gene XRCC1 in survival and clinical outcomes for North Indian population. Blood sample from patients diagnosed with lung cancer was taken. DNA isolation and genotyping were performed for the SNPs of XRCC1 gene. Further, patients were followed up through telephonic conversation after every 2 months for 3 years. Statistical analysis was carried out using Kaplan–Meier to determine the median survival time (MST) and Cox proportional regression model to determine the hazards ratio. Further, logistic regression was used to calculate to calculate the objective response. The mutant genotype for XRCC1 399 is observed to have a better survival (MST = 9.6). Histological stratification did not reveal any association for any SNP except for SCLC subtype in XRCC1 632 with an increased death rate (HR 3.08, p = 0.02). On stratification according to chemotherapy regimen administered; cisplatin/carboplatin + docetaxel was observed to increase survival for XRCC1 399 mutant genotype (AA) (HR 0.26, p = 0.05). Cisplatin/carboplatin + irinotecan increased survival in both heterozygotes (GA) and combined variants (GA + AA) (HR 0.22, p = 0.014; HR 0.23, p = 0.012). The polymorphic variants within the XRCC1 gene have found to play an important role in overall survival of lung cancer patients undergoing specific chemotherapy regimen.


Lung cancer Single nucleotide polymorphism XRCC1 Overall survival Hazards rate Chemotherapy 



Lung cancer


Squamous cell carcinoma




Small cell lung carcinoma


Non-small cell lung carcinoma


DNA repair capacity


Overall survival


Eastern cooperative oncology group


Karnofsky’s response status


Response evaluation criteria in solid tumors


Complete response


Partial response


Stable disease


Progression disease



We would like to express our gratitude to all the subjects who participated in this current study. This work was supported by grant from the Indian Council of Medical Research, New Delhi, India (Grant No. 5/13/126/2011/NCD-III).

Compliance with ethical standards

Conflict of interest


Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12032_2017_923_MOESM1_ESM.docx (32 kb)
Supplementary material 1 (DOCX 31 kb)


  1. 1.
    International Agency for Research on Cancer, Lung Cancer. Estimated Incidence, Mortality and Prevalance Worldwide in 2012. Accessed 10 May 2016.
  2. 2.
    Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    National Comprehensive Cancer Network, Inc., 2016.
  4. 4.
    Rosell R, Lord RVN, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38:217–27.CrossRefPubMedGoogle Scholar
  5. 5.
    Bahl A, Falk S. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Br J Cancer. 2001;84:1143–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett. 2000;159:63–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Sato M, Shames DS, Gazdar AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Wei Q, Cheng L, Hong K, et al. Reduced DNA repair capacity in lung cancer patients. Can Res. 1996;56:4103–8.Google Scholar
  9. 9.
    Shellard SA, Fichtinger- Schepman AM, et al. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs. 1993;4:491–500.CrossRefPubMedGoogle Scholar
  10. 10.
    Dexheimer TS, DNA repair pathways and mechanisms 2013.Google Scholar
  11. 11.
    Chen J, Zhao Q, Shi G, Wang L. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. J Zhejiang Univ Sci B. 2012;13:875–83.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhu G, Lippard SJ. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry. 2009;48:4916–25.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Weaver DA, Crawford EL, Warner KA, Elkhairi F, et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatinchemoresistance in non-small cell lung cancer cell line. Mol Cancer. 2005;4:18.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Au WW, Navasumrit P, Ruchirawat M. Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health. 2004;207:301–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604–8.PubMedGoogle Scholar
  16. 16.
    Lunn RM, Langlois RG, Hsieh LL, et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorinA variant frequency. Cancer Res. 1999;59:2557–61.PubMedGoogle Scholar
  17. 17.
    Sang MY, Hong YC, Heon JP, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:885–91.CrossRefGoogle Scholar
  18. 18.
    Wu JS, Chen YP, Wang LC, et al. Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma. Genet Mol Res. 2014;13:3812–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Zou HZ, Yang SJ. Prediction role of seven SNPs of DNA repair genes for survival of gastric cancer patients receiving chemotherapy. Asian Pac J Cancer Prev. 2012;13:6187–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Li K, Li W. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Mol Cell Biochem. 2013;372:27–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Syamala VS, Syamala V, Sreedharan H, et al. Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an indian report. Pathol Oncol Res. 2009;15:389–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Ang M, Patel MR, Yin X, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2011;17:6542–53.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ke HG, Li J, Shen Y, et al. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2012;13:4413–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Yuan P, Liu L, Wu C, et al. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biol Ther. 2010;10:854–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Navneet S, Ashutosh A, et al. Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of nonsquamous NSCLC patients with pemetrexed-based chemotherapy. Am J Clin Oncol. 2014. doi: 10.1097/COC.0000000000000111.Google Scholar
  26. 26.
    Sharma N, Singh A, Singh N, Behera D, Sharma S. Genetic polymorphisms in GSTM1, GSTT1 and GSTP1 genes and risk of lung cancer in a North Indian population. Cancer Epidemiol. 2015;39:947–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Yin J, Vogel U, Ma Y, et al. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang Z, Wan J, Jin X, et al. Genetic polymorphisms in XRCC1, APE1, ADPRT, XRCC2 and XRCC3 and risk of chronic benzene poisoning in a Chinese occupational population. Cancer Epidemiol Biomarkers Prev. 2005;2614–20.Google Scholar
  29. 29.
    Zhang L, Ma W, Li Y. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Genet Mol Res. 2014;13:228–36.CrossRefPubMedGoogle Scholar
  30. 30.
    Liao W, Shih J, Chang G, et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. JTO Acquis. 2012;7(6):973–81.Google Scholar
  31. 31.
    Osawa K, Nakarai C, Uchino K, et al. XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients. Int J Mol Sci. 2012;13:16658–67.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594–600.CrossRefPubMedGoogle Scholar
  33. 33.
    Jin ZY, Zhao XT, Zhang LN, et al. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res. 2014;13:7617–25.CrossRefPubMedGoogle Scholar
  34. 34.
    Sreeja L, Syamala VS, Syamala V, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol. 2008;134(6):645–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Li Q, Lu C, Ye M, et al. Evaluation of DNA repair gene XRCC1 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Asian Pac J Cancer Prev. 2012;13:191–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Sacerdote C, Guarrera S, Ricceri F, et al. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer. 2013;133:2004–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zaanan A, Dalban C, Emile JFJF, et al. ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatin-based adjuvant chemotherapy. J Cancer. 2014;5:425–32.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Yao C-Y, Huang X-E, Li C, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev. 2009;10(5):859–64.PubMedGoogle Scholar
  39. 39.
    Cao Z, Song J, Wang J, et al. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9:e85357.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yin Z, Zhou B, He Q, et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer. 2009;9:439.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhao W, Hu L, Xu J. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2013;71:1287–95.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhao R, Chen G. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:14909–16.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Cheng C-X, Xue M, Li K, et al. Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. Asian Pac J Cancer Prev. 2012;13:2541–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Hu HQ, Wang F, Du X et al. Genetic variability of XRCC1 influences the treatment outcome of gastric cancer. Genet Mol Res 2016;15.Google Scholar
  45. 45.
    Yuan Z, Li J, Hu R, et al. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. Nat Publ Gr Sci Rep. 2015;5:16482.Google Scholar
  46. 46.
    Hong C-Y, Xu Q, Yue Z, et al. Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. Chin J Cancer. 2009;28:1291–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Amrita Singh
    • 1
  • Navneet Singh
    • 2
  • Digambar Behera
    • 2
  • Siddharth Sharma
    • 1
  1. 1.Department of BiotechnologyThapar UniversityPatialaIndia
  2. 2.Department of Pulmonary MedicinePost Graduate Institute of Education and Medical Research (PGIMER)ChandigarhIndia

Personalised recommendations